Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 27211051 | HLA-DRB1*03 | autoimmune polyendocrine syndrome type 2 | NA | vitamin | NA | lack_of_evidence | |
| among the genetic factors for isolated aad and autoimmune polyendocrine syndrome type 2, a key role is played by hla class ii genes: hla-drb1*0301-dqa1*0501-dqb1*0201 and drb1*04-dqa1*0301-dqb1*0302 are positively, and drb1*0403 is negatively, associated with genetic risk for aad. | |||||||
| 27312803 | HLA-DR (HLA-DR) | fibroatheroma | NA | NA | NA | positive | |
| progressive fibroatheromatous lesions, including vulnerable plaques, showed increasing numbers of nk cells and fascin-positive cells mainly localized to the media and adventitia whereas the m1/m2 ratio and level of macrophage activation (hla-dr and neopterin) remained unchanged. | |||||||
| 27327535 | HLA (HLA) | lentigines | Caucasian | NA | NA | unclassified | |
| a genome-wide association study in caucasian women suggests the involvement of hla genes in the severity of facial solar lentigines. | |||||||
| 27327535 | HLA (HLA) | lentigines | Caucasian | NA | NA | unclassified | |
| overall, our results point to several mechanisms involved in the severity of facial lentigines, including hla/immunity and the melanogenesis pathway. | |||||||
| 27543873 | HLA-DR (HLA-DR) | langerhans cell sarcoma | NA | NA | NA | positive | |
| h and e stained sections revealed a langerhans cell sarcoma, and immunohistochemistry was performed additionally; cd68, cd163, cd14, fascin, hla-dr, lysozyme, s100 cd1a and langerin showed a positive reaction, while cd20, cd30, cd34, cd31, pan-cytokeratin, ae/1ae3, sma, desmin, ema, erg, ini-1, cd21, cd4, plap, mpo and cd117c were negative. | |||||||
| 27553765 | HLA-DR (HLA-DR) | placental insufficiency | NA | NA | NA | positive | |
| study revealed imbalance of immune parameters, caused by placental insufficiency (increase natural killers (cd16(+) , cd56(+) ), b lymphocytes (cd19(+) cd3(-) ), t and b lymphocytes with hla-dr(+) antigen, and early activation of immune cells (by cd25(+) ), as well as disorders in apoptotic mechanisms (by cd95(+) )). | |||||||
| 27586161 | HLA-DRB1*10 | tauopathy | NA | NA | NA | unclassified | |
| the disorder shows a remarkable association with the hla-dqb1*0501 and hla-drb1*1001 alleles, and postmortem studies demonstrate a novel neuronal tauopathy predominantly involving the hypothalamus and tegmentum of the brainstem. | |||||||
| 27586161 | HLA-DQB1*05 | tauopathy | NA | NA | NA | unclassified | |
| the disorder shows a remarkable association with the hla-dqb1*0501 and hla-drb1*1001 alleles, and postmortem studies demonstrate a novel neuronal tauopathy predominantly involving the hypothalamus and tegmentum of the brainstem. | |||||||
| 29796717 | HLA (HLA) | tauopathy | NA | NA | NA | unclassified | |
| the disease presents a robust hla association, and the neuropathological examination shows a novel neuronal tauopathy with predominant hypothalamic and brainstem involvement.recent findingsmost patients (> 80%) present sleep-related vocalizations with movements and behaviors and sleep-disordered breathing. | |||||||
| 29796717 | HLA (HLA) | sleep-disordered breathing | NA | NA | NA | unclassified | |
| the disease presents a robust hla association, and the neuropathological examination shows a novel neuronal tauopathy with predominant hypothalamic and brainstem involvement.recent findingsmost patients (> 80%) present sleep-related vocalizations with movements and behaviors and sleep-disordered breathing. | |||||||
Copyright 2024